Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片
Product Description

  • Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.

    • Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.

    Expanding patient pool – prostate cancer incidence is rising annually, driving rigid growth in drug demand.

    High guideline status – Grade I recommendation in NCCN and CSCO guidelines for mHSPC and nmCRPC.

    Read more Show less

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
      60MG
    • Selling Points
      Top selling product used for treatment of prostate cancer.
    • Supplied from
      China
    • Measured In
      piece
    More specifications Fewer specifications

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile

    More Products from Biotech Pharmaceutical Co., Ltd. (3)

    • Axitinib Tablets / 阿昔替尼片

      Product Axitinib Tablets / 阿昔替尼片

      • Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.

      The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.
      ...
    • Ebidetide Injection (JY09) / 益百得肽注射液

      Product Ebidetide Injection (JY09) / 益百得肽注射液

      1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ...
    • Nimoutuzumab Injection

      Product Nimoutuzumab Injection

      Our flagship product, Nimotuzumab, is a humanized anti‑EGFR monoclonal antibody. Since its launch in China in 2008, it has been approved for the treatment of nasopharyngeal carcinoma, pancreatic cancer, and head and neck tumors, demonstrating robust clinical efficacy and a favorable safety profile. Annual ...